ArticleFrontiers in immunology2026
Myeloid miR-155 deficiency exacerbates viral encephalitis by hindering M1 macrophage polarization due to impaired NLRP3 inflammasome activation in extraneural tissues.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: miR-155 regulates diverse inflammatory responses; however, its role in neurotropic virus-induced CNS inflammation, particularly in specific immune cell subsets, remains unclear. This study aimed to identify the immune cell population in which miR-155 is required for protection against Japanese encephalitis virus (JEV) and to elucidate the underlying mechanisms. Methods: Conditional miR-155 knockout mice with cell type-specific deletion in myeloid cells, dendritic cells (DCs), T cells, or B cells were generated using Cre-LoxP technology. Following JEV infection, we assessed survival, viral burden, type I interferon responses, M1 macrophage polarization, and NLRP3 inflammasome activation. Downstream targets of miR-155 and the effects of NLRP3 inhibition or IL-1α/IL-1β neutralization were also evaluated. Results: Myeloid cell-specific deletion of miR-155, but not its deletion in other immune cell types, significantly increased susceptibility to JEV infection and exacerbated neuroinflammation. This phenotype was associated with elevated viral burdens in both lymphoid and CNS tissues, impaired type I interferon responses, defective M1 macrophage polarization, and reduced NLRP3 inflammasome activation. Mechanistically, Peli1, Jarid2, and Bcl6 were identified as key downstream targets of miR-155 that regulate M1 polarization and inflammasome activity. Furthermore, pharmacological inhibition of NLRP3 or neutralization of IL-1α and IL-1β further worsened disease severity and suppressed M1 polarization. Discussion: These findings demonstrate that miR-155 in myeloid cells, particularly macrophages, is essential for orchestrating protective immune responses during neurotropic virus-induced CNS inflammation by promoting M1 macrophage polarization and NLRP3 inflammasome activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.